Nutcracker Therapeutics Presenting on Nutshell™ mRNA Delivery Technology at the 2023 Oligonucleotide and Peptide Therapeutics Conference

EMERYVILLE, Calif., May 2, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, will present at this year’s TIDES USA, or the Oligonucleotide and Peptide Therapeutics conference, being held May 7-10, 2023 in San Diego, CA.

Nutcracker Therapeutics has developed its Nutshell™ platform of peptoid delivery vehicles for use with its mRNA therapies. This unique class of structurally-tunable peptoids contains both a hydrophobic domain and an amino-functionalized cationic domain to self-assemble with mRNA cargos, enabling the safe and effective delivery of mRNA for Nutcracker’s therapeutic programs.

Presentation Details

Title: Delivery in a Nutshell™: Activity-informed design of cationic peptoids with enhanced efficacy for the uptake and expression of mRNA therapeutics
Presenter: Colin McKinlay, Senior Director, Chemistry and Delivery Technologies
Session: Targeted Therapies and Delivery of Macromolecules
Date: May 9, 2023 at 9:00 am PT

“We have taken some of the most difficult challenges in mRNA therapeutic delivery head on, building our Nutshell delivery solution to complement our therapeutic programs and round out our end-to-end drug development process,” remarked Chief Executive Officer Igor Khandros, Ph.D. “Through our differentiated nanoparticle approach, we look to overcome hurdles of chemical instability, innate immunogenicity, and inefficient in vivo delivery to fully realize RNA’s clinical potential.”

About Nutcracker Therapeutics, Inc.

Nutcracker Therapeutics, Inc. is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker’s technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches.

For more information, visit

Media Contact:

Azeem Zeekrya
(312) 506-5244